Proposed capability · subject to evidence gates
Challenge whether a model is relevant before larger studies inherit its assumptions.
The technical case remains rigorous while the public meaning stays clear and inspectable.
A proposed translational environment could evaluate model relevance, barrier function, transport, exposure-response, imaging and bioanalytical endpoints using organoids, microphysiological systems or other justified new-approach methodologies.
The purpose would be to expose uncertainty in the model-to-human inference. A signal in a chip, organoid or cell system would not establish human safety, efficacy, dose, clinical utility or regulatory acceptability.
Researchers increasingly use miniature human-relevant systems to ask how a tissue might respond. These models can be useful, but they are still models.
The proposed laboratory would test how reliable a model is for one decision, and make its limits as visible as its promising signals.
Does a justified microphysiological barrier model remain stable and discriminating enough to support one defined permeability or toxicity-screening decision?
Decision useAccept the model for a narrow exploratory use, redesign it, compare with an external specialist or stop the inference.
Apparent permeability relates transport rate to exposed area and starting concentration. It is a model-specific measurement, not a prediction of human absorption on its own.
Papp = (dQ/dt)/(A·C₀)Every system would need justified demand, competent operators, utilities, safety controls, maintenance and an accountable intended use.
Maintain a defined multicellular or barrier model under controlled flow.
Acquire repeatable morphology and marker measurements across a defined study.
Resolve spatial localisation or barrier structure for a stated endpoint.
Measure barrier integrity and transport under declared assumptions.
Characterise defined cellular states or response markers.
The translational scientist, biosafety authority and study sponsor agree the intended use, model limitations and advance/stop criteria before execution.
No model or algorithm may convert an in-vitro signal into a clinical safety, efficacy, diagnosis, dose or patient-treatment conclusion.
A model-applicability statement with measurement performance, limitations, uncertainty and a justified next-study recommendation.
Stop when provenance, model stability, controls, biological relevance, measurement performance or lawful use cannot support the intended inference.
Shared governance connects Glasgow and Hyderabad. Climate, infrastructure, demand and regional value keep their designs materially different.
The campus expression is a planning hypothesis only. It does not represent a secured site, approved design, funded programme, partner commitment or operating capability.
The campus expression is a planning hypothesis only. It does not represent a secured site, approved design, funded programme, partner commitment or operating capability.
A defined human-relevant model question before later studies.
A model-suitability and uncertainty package.
A governed route to test whether a research model supports translation.
A reproducible study record with ownership and publication terms agreed.
Independent challenge against a declared context of use.
A fit-for-purpose evaluation, not certification or endorsement.
Future intent is not current performance. Every measure requires a defined workflow, boundary and accountable record.
Illustrative proposed experiment envelope. This is not performed work, a protocol, an installed capability, a service offer, a validated method or evidence of an operating laboratory. No GMP, GLP, manufacturing-licence, clinical or regulatory-readiness status is claimed.
Lawful and consent-compatible human material route where applicable
Ethics, biobank and data approvals matched to the work
Risk-based biosafety controls
Predeclared model context of use
No patient treatment, diagnosis or clinical-performance claim
Qualified external route for activity beyond approved campus scope
These sources inform the proposed programme. They do not prove VARUNÉ capability, affiliation, performance, compliance or regulatory acceptance.
Describes tissue-chip work intended to improve prediction of drug safety or toxicity and advance human-relevant models.
CaveatThe programme does not make every tissue chip validated or suitable for a specific regulatory decision.
Open primary sourceProvides current FDA context for organoids, organs-on-chips, cell-based assays and in-silico approaches.
CaveatRegulatory use remains context-, method- and evidence-specific.
Open primary sourceSupports risk- and evidence-based decisions on biological laboratory design, containment, practice, training and waste.
CaveatThe manual does not determine the controls for an undefined activity; a documented local risk assessment remains necessary.
Open primary sourceA conversation or published concept does not create a partnership, service, installed capability, programme commitment or authority to use another organisation’s name.